

CONVENTION ON INTERNATIONAL TRADE IN ENDANGERED SPECIES
OF WILD FAUNA AND FLORA



Twenty-fourth meeting of the Animals Committee
Geneva, (Switzerland), 20-24 April 2009

Review of Significant Trade in specimens of Appendix-II species

EVALUATION OF THE REVIEW OF SIGNIFICANT TRADE

1. This document has been prepared by the Secretariat.
2. The Annex to the present document contains the conclusions of the 18th meeting of the Plants Committee (Buenos Aires, March 2009) on this subject.

CONVENTION ON INTERNATIONAL TRADE IN ENDANGERED SPECIES
OF WILD FAUNA AND FLORA



Eighteenth meeting of the Plants Committee
Buenos Aires (Argentina), 17-21 March 2009

Evaluation of the Review of Significant Trade

With the addition of the Canadian Scientific Authority Working Group under subparagraph d), the Committee agreed with the proposed composition of the advisory working group in paragraph 5 of the document. The Committee further agreed to nominate the specialist on botanical nomenclature: (Mr McGough) as the representative of the Plants Committee on the advisory working group and that he should co-chair the advisory working group with the representative of the Animals Committee.

Case studies, listed in order of priority:

1. *Prunus africana*
2. *Pericopsis elata*
3. Madagascar, country study

Modus operandi

The Committee supported the *modus operandi* proposed by the Secretariat and recommended that it be treated as general guidelines and not restrain the Advisory Group from making further amendments.

The following should be taken into account:

- a) Choice of consultants

The Secretariat should utilize the expertise of the Advisory Group and the Animals and Plants Committees in identifying consultants with appropriate expertise to carry out the Review.

- b) Case studies

The Committee encourages Parties to participate in the evaluation by carrying out case studies in collaboration with and under the direction of the Advisory Group.

- c) Compliance issues

The case of *Prunus africana* and the Seven Asian species of Medicinal Plants [see document PC18 Doc. 8.5 (Rev 1)] should be considered when reviewing issues related to compliance.